Abstract:Hepatocellular carcinoma (HCC) is an aggressive malignancy, and its effective treatment has been hampered by drug resistance. Extracellular vesicle (EV) delivery of TNF-related apoptosis-inducing ligand (TRAIL) (EV-T) was demonstrated to be superior to recombinant TRAIL (rTRAIL) for cancer treatment previously. And AZD5582, a potent antagonist of inhibitors of apoptosis proteins (IAPs) can potentiate apoptosis-based cancer therapies. However, the combination of EV-T and AZD5582 has never been examined for their possible apoptosis inducing synergism in cancers. In this study, we proposed and tested the combination of EV-T and AZD5582 as a potential novel therapy for effective treatment of HCC. Two HCC lines Huh7 and HepG2 that are both resistant to rTRAIL were examined. The results confirmed that AZD5582 and EV-T are synergistic for apoptosis induction in some cancer lines including Huh7 and HepG2 while sparing normal cells. More importantly, this study revealed that TRAIL sensitization by AZD5582 is mediated through the concomitant suppression of anti-apoptotic factors including cFLIP, MCL-1, and IAPs (XIAP, Survivin and cIAP-1). Particularly the downregulation of cFLIP and IAP's appeared to be essential and necessary for the synergism between AZD5582 and TRAIL. In vivo, we first time demonstrated that the combined therapy with low doses of AZD5582 and EV-Ts triggered drastically enhanced apoptosis leading to the complete eradication of Huh7 tumor development without any apparent adverse side effects examined. We thus have unraveled the important molecular mechanism underlying TRAIL sensitization by AZD5582, rationalizing the next development of a combination therapy with AZD5582 and EV-T for HCC treatment.Key messagesIt confirmed the TRAIL sensitization by AZD5582, a potent antagonist of IAPs in hepatocarcinoma.It revealed that the sensitization is via the concomitant suppression of antiapoptotic factors including cFLIP, MCL-1, and IAPs.The downregulation of cFLIP and IAPs like Survivin appeared to be essential and necessary for the synergism between AZD5582 and nanosomal TRAIL.In vivo the combined therapy with AZD5582 and nanosomal TRAIL led to complete eradication of hepatocarcinoma tumors.This study has rationalized the next development of a combination therapy with AZD5582 and nanosomal TRAIL for cancer treatment.

Combination of PHA-767491 with TRAIL Inhibits Proliferation of Hepatocellular Carcinoma Bel-7404 Cells

Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.

Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.

Study on Inhibition of Hepatoma Carcinoma Cell Growth by PHA-767491

Anti-liver Cancer Activity of TNF-related Apoptosis-Inducing Ligand Gene and Its Bystander Effects.

Effects of Different Chemotherapeutic Agents on Reversing the Acquired Resistance to TRAIL Gene in DLD1 Colon Cancer Cells

Effects of TRAIL combined with cisplatin on Hep-2 laryngeal squamous carcinoma in vitro

[Synergistic Effects and Mechanisms of Combined Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Chemotherapeutic Drugs or Radiotherapy in Killing Laryngeal Squamous Carcinoma Cells in Vitro].

The Apoptotic Pathway of Laryngeal Squamous Carcinoma Cell Line Induced by Combined TRAIL with Chemotherapeutic Drugs or Radiotherapy

Enhanced Anti-Tumor Activity by the Combination of TRAIL/Apo-2L and Combretastatin A-4 Against Human Colon Cancer Cells Via Induction of Apoptosis in Vitro and in Vivo.

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Synergistic Combination of Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid and Oncolytic Adenovirus Zd55-Trail As A Therapy Against Cervical Cancer

EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma

Experimental Study on Apoptosis of Osteosarcoma Cell Induced by TRAIL Combined with IFN-γ

Activity of TRAIL Gene Modification Combined with DOX on Human Colon Cancer Cell Line RKO

Bortezomib Overcomes Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance in Hepatocellular Carcinoma Cells in Part Through the Inhibition of the Phosphatidylinositol 3-Kinase/akt Pathway

Synergistic Anti-Cancer Activity by the Combination of TRAIL/APO-2L and Celastrol

Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers

A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes.

Combination Of Trail And Actinomycin D Liposomes Enhances Antitumor Effect In Non-Small Cell Lung Cancer

Inhibition effects of TRAIL combined with small molecule drugs on pancreatic cancer cells